Prognostic Significance of Long-term HbA1c Variability for All-Cause Mortality in the ACCORD Trial
The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: The association between high glycemic variability and all-cause mortality has been widely investigated in epidemiological studies but rarely validated in glucose-lowering clinical trials. We aimed to identify the prognostic significance of visit-to-visit HbA1c variability in treated patients in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial population. RESEARCH DESIGN AND METHODS: We studied the risk of all-cause mortality in relation to long-term visit-to-visit HbA1c variability, expressed as coefficient of variation (CV), variability independent of the mean (VIM), and average real variability (ARV), from the 8th month to the transition from intensive to standard glycemic therapy. Multivariable Cox proportional hazards models were used to estimate adjusted hazard ratio (HR) and 95% CI. RESULTS: Compared with the standard therapy group (n = 4,728), the intensive therapy group (n = 4,755) had significantly lower mean HbA1c (6.6% [49 mmol/mol] vs. 7.7% [61 mmol/mol], P < 0.0001) and lower CV, VIM, and ARV (P < 0.0001). In multivariate adjusted analysis, all three HbA1c variability indices were significantly associated with total mortality in all patients as well as in the standard- and intensive-therapy groups analyzed separately. The hazard ratios for a 1-SD increase in HbA1c variability indices for all-cause mortality were 1.19 and 1.23 in intensive and standard therapy, respectively. Cross-tabulation analysis showed the third tertile of HbA1c mean and VIM had significantly higher all-cause mortality (HR 2.05; 95% CI 1.17–3.61; P < 0.01) only in the intensive-therapy group. CONCLUSIONS: Long-term visit-to-visit HbA1c variability was a strong predictor of all-cause mortality. HbA1c VIM combined with HbA1c mean conferred an increased risk for all-cause mortality in the intensive-therapy group.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Stratton, I. M. (2000) · BMJ · doi:10.1136/bmj.321.7258.405 · Cited by 9,059
Effects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802987 · Cited by 7,397
Glucose control and vascular complications in veterans with type 2 diabetes
Duckworth, W., Abraira, C., Moritz, T., Reda, D., Emanuele, N., Reaven, P. D., Zieve, F. J., Marks, J., Davis, S. N., Hayward, R., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808431 · Cited by 4,762
Self-citationRothwell, P. M., Howard, S. C., Dolan, E., O'Brien, E., Dobson, J. E., Dahlöf, B., Sever, P. S., & Poulter, N. R. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60308-x · Cited by 1,784 · cited 2×
“Long-term visit-to-visit HbA1c variability was evaluated using three or more HbA1c measures from the 8th month to the transition, calculating individual participant coefficient of variation (CV), variation independent of the mean (VIM) (20), and average real variability (ARV) (21).”
MethodLong-term effects of intensive glucose lowering on cardiovascular outcomes
The ACCORD Study Group (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1006524 · Cited by 1,035
Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial: Design and Methods
Buse, J. B. (2007) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2007.03.003 · Cited by 661
Hemmingsen, B., Lund, S. S., Gluud, C., Vaag, A., Almdal, T., Hemmingsen, C., & Wetterslev, J. (2011) · BMJ · doi:10.1136/bmj.d6898 · Cited by 386
Hirakawa, Y., Arima, H., Zoungas, S., Ninomiya, T., Cooper, M., Hamet, P., Mancia, G., Poulter, N., Harrap, S., Woodward, M., et al. (2014) · Diabetes Care · doi:10.2337/dc14-0199 · Cited by 363 · cited 1×
“was the first large-scale study to report the effects of variability in both HbA1c and fasting glucose on a variety of allcause mortality in type 2 diabetes, including macrovascular events (27).”
BackgroundGlycemic Variation and Cardiovascular Risk in the Veterans Affairs Diabetes Trial
Zhou, J. J., Schwenke, D. C., Bahn, G., & Reaven, P. (2018) · Diabetes Care · doi:10.2337/dc18-0548 · Cited by 131
Self-citation
Cited by
Glycemic variability: adverse clinical outcomes and how to improve it?
Zhou, Z., Sun, B., Huang, S., Zhu, C., & Bian, M. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01085-6 · Cited by 255
Lee, S., Zhou, J., Wong, W. T., Liu, T., Wu, W. K. K., Wong, I. C. K., Zhang, Q., & Tse, G. (2021) · BMC Endocrine Disorders · doi:10.1186/s12902-021-00751-4 · Cited by 97
Chen, J., Yi, Q., Wang, Y., Wang, J., Yu, H., Zhang, J., Hu, M., Xu, J., Wu, Z., Hou, L., et al. (2022) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2022.110085 · Cited by 69
Kaze, A. D., Santhanam, P., Erqou, S., Ahima, R. S., & Echouffo-Tcheugui, J. B. (2020) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2020-001753 · Cited by 40
Significance of Glycemic Variability in Diabetes Mellitus
Kusunoki, Y., Konishi, K., Tsunoda, T., & Koyama, H. (2022) · Internal Medicine · doi:10.2169/internalmedicine.8424-21 · Cited by 40
Metadata
- Authors
- Sheng, C.-S., Tian, J., Miao, Y., Cheng, Y., Yang, Y., Reaven, P. D., Bloomgarden, Z. T., & Ning, G.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2020-03-30
- Volume
- 43
- Issue
- 6
- Pages
- 1185-1190
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W3013603544
- Cited by
- 109
- References
- 10
- FWCI
- 11.94
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Prognostic Significance of Long-term HbA1c Variability for All-Cause Mortality in the ACCORD Trial. https://app.cochat.ai/papers/10.2337/dc19-2589
- The paper
- Sheng, C.-S., Tian, J., Miao, Y., Cheng, Y., Yang, Y., Reaven, P. D., Bloomgarden, Z. T., & Ning, G. (2020). Prognostic Significance of Long-term HbA1c Variability for All-Cause Mortality in the ACCORD Trial. Diabetes Care. https://doi.org/10.2337/dc19-2589
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.